Key principles of antiretroviral pharmacology

B Dionne - Infectious Disease Clinics, 2019 - id.theclinics.com
Antiretroviral pharmacology has progressed significantly since the Food and Drug
Administration's (FDA) approval of the first antiretroviral, the nucleoside reverse …

The changing landscape of HIV-associated kidney disease

NE Diana, S Naicker - Nature Reviews Nephrology, 2024 - nature.com
The HIV epidemic has devastated millions of people globally, with approximately 40 million
deaths since its start. The availability of antiretroviral therapy (ART) has transformed the …

[PDF][PDF] BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

L Waters, A Winston, I Reeves, M Boffito… - HIV …, 2022 - discovery.ucl.ac.uk
The overall purpose of these guidelines is to provide guidance on best clinical practice for
antiretroviral therapy (ART) and management of adults living with human immunodeficiency …

[HTML][HTML] Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

HT Pham, MA Xiao, MAV Principe, A Wong… - Drugs in …, 2020 - ncbi.nlm.nih.gov
As part of a combined antiretroviral regimen, doravirine is safe and effective at suppressing
viral replication in both treatment-naive and treatment-experienced adults living with human …

Antiretroviral stewardship: top 10 questions encountered by stewardship teams and solutions to optimize therapy

MH Chang, Y Guo, A Acbo, H Bao, T McSweeney… - Clinical Therapeutics, 2024 - Elsevier
Purpose Infectious disease pharmacists and physicians overseeing antimicrobial
stewardship programs possess expertise and often advanced certification in management of …

Antiretrovirals for People with HIV on Dialysis

D Dandachi, M Fabricius, B Saad… - AIDS Patient Care …, 2022 - liebertpub.com
In the era of widespread use of antiretroviral therapy (ART), people with HIV (PWH) have a
near-normal life expectancy. However, PWH have high rates of kidney diseases and …

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

A Ciccullo, G Baldin, A Borghetti… - Expert review of anti …, 2020 - Taylor & Francis
Introduction: Recent data on the 2-drug regimen (2DR) with dolutegravir (DTG) plus
lamivudine (3TC) have shown high efficacy and tolerability both in treatment-naïve and …

Doing more with less: review of dolutegravir-lamivudine, a novel single-tablet regimen for antiretroviral-naïve adults with HIV-1 infection

BA Santevecchi, S Miller… - Annals of …, 2020 - journals.sagepub.com
Objective: To review data on efficacy and safety of dolutegravir (DTG) and lamivudine (3TC)
in treatment-naïve adults with HIV-1 infection. Data Sources: Phase III clinical trials and …

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

K Mounzer, L Brunet, CM Wyatt, JS Fusco… - Aids, 2021 - journals.lww.com
Objectives: To assess the risk of adverse diagnoses and laboratory abnormalities
associated with a 300 or 150 mg daily dose of lamivudine (3TC) initiated by people with HIV …

[HTML][HTML] An overview of the current hepatitis B treatment strategies after liver transplantation

AD Moghadam, P Eslami, AD Beirami… - Middle East Journal …, 2021 - ncbi.nlm.nih.gov
Currently, liver transplantation (LT) is considered as the only option for the treatment of
patients with various causes of liver failure, including patients with chronic hepatitis B virus …